4th annual partnership opportunities in drug delivery · 9/22/2014 · – liquidia ! envisia –...

PARTNERSHIPS IN DRUG DELIVERY

4th Annual

PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY Boston - Oct 14-15, 2014

3/10/2006 Copyright 2003 --CONFIDENTIAL

2 Micron Sphere


Drug Delivery

Opportunities

Partnerships

Due Diligence 3/10/2006 Copyright 2003 --CONFIDENTIAL

2 Micron Sphere

PARTNERSHIPS IN DRUG DELIVERY Partnership areas in 2014

•  Half-life extension •  Novo Nordisk – Caisson Biotech: expansion of license agreement for

HEPtune™ (exclusive rights for insulin conjugated to HEPtune, non-

exclusive rights to leverage the HEPtune ™ in areas such as diabetes,

hGH, obesity, inflammatory diseases)

•  Novozymes – ThioLogic: collaboration to offer drug-albumin

conjugation platform

•  Novozymes – Janssen: evaluation of albumin-based VELTIS® platform

by Janssen


•  Vaccines •  Ascend – 3M: research collaboration to evaluate 3M’s TLR 7/8

agonist in combination wit ASN’s immunotherapy platform for solid

tumors

•  Pfizer – Ichor: collaboration & license agreement for Pfizer to use

Ichor’s TriGrid™ i.m. electroporation technology to facilitate clinical

administration of DNA-based vaccines as part of its preclinical

cancer vaccine-based immunotherapy research program

•  Selecta -3SBio: exclusive license agreement to develop a novel

class of targeted antigen-specific immune tolerance treatments

based on SVP™, to treat gout using Uricase PEG-20 in patients at

risk of immunogenicity.(“first non-immunogenic version of

uricase.”)


•  Ocular •  Drug delivery companies spin-out business dedicated to ophtha

–  Liquidia à Envisia

–  Q Chips à OpsiRx

•  Allergan – Innocore: exclusive license of Inocore’s Synbiosys™ multi-

block co-polymers

•  Targeted delivery •  MedImmune – bioasis: BBB

•  Sun Moral (Sihuan Pharma) – BBB Therapeutics: BBB

•  Roche – BIND: Targeting in areas outside of oncology


•  Targeted devices •  BioCardia – CellProThera: use of BioCardia’s Helix Transendocardial

Delivery System for delivery of in-vitro expanded peripheral blood

CD34+ stem cells

(Ph II: acute myocardial infarction)

•  Pfizer – Medgenesis: agreement granting Pfizer an exclusive,

worldwide option to license Medgenesis’ glial cell line-derived

neurotrophic factor (GDNF) protein and convection enhanced delivery

(CED) technology to be used in research for potential treatments for

Parkinson’s disease

•  Mallinckrodt – Medtronic: multiyear agreement to develop drugs for

chronic pain and severe spasticity using Medtronic’s

SynchroMed® Programmable Infusion System for intrathecal use


•  Mucosal delivery •  Grünenthal – AcelRx: pain management drug device combination

•  Transdermal •  Corium goes IPO

•  Corium – Aequus: evaluation of transdermal delivery for aripiprazole

•  Sanofi – Bioserentach: development of patch-type formulation

(Dissolving Microneedle Chip) for lixisenatide (GLP-1 peptide)

•  Novo Nordisk – zosano: development of microneedle patch for semaglutide

•  New Frontier Science group at Takeda – Pantec Biosolutions: investigation of

mid-infrared laser ablation technology for rapid and painless treatments for

inflammatory skin diseases


•  Inhalation •  Skyepharma – Pulmagen: acquisition of novel inhaled therapy platform

SKP-2075 as anti-inflammatory treatment for COPD

•  Astra Zeneca – Synairgen: exlusive license of SNG001, a novel inhaled

interferon beta for treating respiratory tract viral infections in patients with

severe asthma

•  Invion Ltd – 3M: inhaled versions of nadolol for inflammatory airway

diseases

•  Vectura acquires Activaero

•  Dance Biopharm – Harmony Asset: joint venture in China to develop inhaled

insulin product Adagio(liquid formulation in handheld aerosol device)

•  Accorda – Civitas Therapeutics: acquisition of ARCUS platform (precise

delivery of large drug quantities in a breath-actuated inhaler) and CVT-301

program (L-dopa) for Parkinson’s (off episodes)

PARTNERSHIPS IN DRUG DELIVERY Is 2014 the year of inhalation ?

Paris and Valencia, Calif. - August 11, 2014 - Sanofi and MannKind Corporation announced

today that they have entered into a worldwide exclusive licensing agreement for development

and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting

inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to

launch Afrezza in the United States in the first quarter of 2015.

Under the collaboration and license agreement, Sanofi will be responsible for global

commercial, regulatory and development activities. Under a separate supply agreement,

MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. In

addition, the companies are planning to collaborate to expand manufacturing capacity to

meet global demand as necessary.

PARTNERSHIPS IN DRUG DELIVERY Predicting drug delivery

success in zebrafish

F. Yanik D. Anderson

PARTNERSHIPS IN DRUG DELIVERY Tackling “holy grails”

Sep 22, 2014


Fireside Chat with: Robert Langer, PhD David H. Koch Institute Professor, MIT Art Tipton, Southern Research Ins:tute Barbara Lueckel, Roche supported by: Jessica Ballinger, Biogen Idec


2013: Wolf Prize in Chemistry for conceiving and implementing advances in polymer chemistry that provide both controlled drug-release systems and new biomaterials 2013: United States National Medal of Technology and Innovation from President Obama 2012: Priestley Medal, the highest honor conferred by the ACS for distinguished service in the field of chemistry 2012: Perkin Medal, recognized as the highest honor given for outstanding work in applied chemistry in the US 2011: Warren Alpert Foundation Prize 2011: The Economist's Innovation award in the category of bioscience for his proven successes in drug-delivery and tissue engineering 2008: Finland's Millennium Technology Prize for developing innovative biomaterials for controlled drug release.[30] 2008: Prince of Asturias Award for Scientific Research 2008: Langer received the Max Planck Research Award 2008 2006: United States National Medal of Science from President George W. Bush 2002: Charles Stark Draper Prize (considered the equivalent of the Nobel Prize for engineers) 2002 Dickson Prize in science

2014: Langer received the Kyoto Prize awarded annually indeed to those who have contributed significantly to the scientific, cultural, and spiritual betterment of mankind 2014: Langer was awarded the Breakthrough Prize in Life Sciences for his work and discoveries that extend human life (a monetary award, funded by internet entrepreneurs – chairman of the Board: A. Levinson) 2014: The Chemical Heritage Foundation (CHF) and the Biotechnology Industry Organization (BIO) selected Robert Langer as the winner of the 2014 Biotechnology Heritage Award for significant contribution to the growth of biotechnology

PARTNERSHIPS IN DRUG DELIVERY "Bob is a master at asking questions that lead to innovations that change the world. Over and over again, Bob has built and led incredible teams to solve critical unmet medical needs“ -----Justin Hanes

"Bob, by his own example and his constant encouragement, has created a culture in his MIT lab that students and post-docs want to be a part of. One would be hard-pressed to find a lab with this combination of science, creativity, productivity, and enthusiasm anywhere else in the world.“ -----John Santini MicroCHIPS, OnDemand, ApoGen Biotechnologies, Inc.

PARTNERSHIPS IN DRUG DELIVERY “Bob is an excellent scientist, a highly prolific inventor, and an extremely successful entrepreneur. He is also a great mentor to many of us. His passion to make a different has been and will always be an inspiration to me.” -----Hongming Chen

“When I asked Bob how achieved his success, he looked straight at me and said "I surround myself with people who are smarter than me". ?????? . It was shocking to hear this statement so matter-of-factly coming from him, as Bob is the smartest person I know. With that statement, he takes away the awe. While many of us feel that we are in the presence of pure genius, he flips it back and makes one feel that we are just as smart - which is empowering. His statement made me feel that he believed in me and motivated me to work that much harder to meet his expectations.” -----Kathryn Uhrich

PARTNERSHIPS IN DRUG DELIVERY “Bob gave me advice when I was starting my independent career. He said that good researchers know how to answer scientific questions, but great researchers know which questions to ask. Bob is a master at identifying the important questions to work on.” -----Mark Prausnitz

“One take-home lesson for me was recognizing that science really is a team sport - one that requires multiple talents from a diverse group, with people who are not afraid to make mistakes.” -----Kathryn Uhrich

PARTNERSHIPS IN DRUG DELIVERY “Bob always, no matter how crazy or busy he was, made time for his students. He allowed us to meet with him when we needed his input, his advice, or just his moral support. I always felt that I had his full and enthusiastic support, and that is so critical to a young person. The best compliment I can give to him is that I have tried to model my own interactions with students and fellows as closely as possible to the great example he provided to me.” -----David Mooney

“What is amazing about Bob is the enormous enthusiasm, the ability to find the brightest people to work with and constantly motivate them.” -----Edith Mathiowitz


“Bob’s approach to science in terms of thinking of big ideas and following up on them with contagious enthusiasm and relentless efforts is truly inspirational and is the prime reason that me and generations of other students have chosen to pursue an academic career” -----Samir Mitagotri

4th annual partnership opportunities in drug delivery · 9/22/2014 · – liquidia ! envisia –...

Documents